Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

• Published in: Science translational medicine Vol. 10; no. 465
• Main Authors: Gordon, Richard, Albornoz, Eduardo A, Christie, Daniel C, Langley, Monica R, Kumar, Vinod, Mantovani, Susanna, Robertson, Avril A B, Butler, Mark S, Rowe, Dominic B, O'Neill, Luke A, Kanthasamy, Anumantha G, Schroder, Kate, Cooper, Matthew A, Woodruff, Trent M
• Format: Journal Article
• Language: English
• Published: United States 31.10.2018
• Subjects: Administration, Oral; alpha-Synuclein - toxicity; Animals; CARD Signaling Adaptor Proteins - metabolism; Disease Models, Animal; Dopaminergic Neurons - drug effects; Dopaminergic Neurons - metabolism; Dopaminergic Neurons - pathology; Extracellular Space - metabolism; Furans - administration & dosage; Furans - pharmacology; Humans; Inflammasomes - antagonists & inhibitors; Inflammasomes - metabolism; Mice; Microglia - metabolism; Nerve Degeneration - pathology; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Parkinson Disease; Protein Aggregates - drug effects; Pyroptosis; Substantia Nigra - drug effects; Substantia Nigra - pathology; Sulfonamides - administration & dosage; Sulfonamides - pharmacology

Parkinson's disease (PD) is characterized by a profound loss of dopaminergic neurons in the substantia nigra, accompanied by chronic neuroinflammation, mitochondrial dysfunction, and widespread accumulation of α-synuclein-rich protein aggregates in the form of Lewy bodies. However, the mechanis...